Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Eastgate Biotech Corp. (OTC: ETBI).

Full DD Report for ETBI

You must become a subscriber to view this report.


Recent News from (OTC: ETBI)

EastGate Biotech Appoints World-Renowned Diabetes Key Opinion Leader Dr. Lalit Upadhyay for Upcoming Initiatives
Key Opinion Leader spreading awareness of diabetes endorses the company's liquid insulin mouth rinse solution for Type 2 diabetes and pre-diabetes patients WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / November 19, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical comp...
Source: ACCESSWIRE
Date: November, 19 2018 09:00
EastGate Biotech Receives Approval to Commence a Phase 2 Trial for Liquid Insulin Mouth Rinse Solution Addressing Patient Compliance in the Type 2 Diabetes Market
DRAP (Drug Regulatory Authority Pakistan) provided approval to commence studies of INSUGIN in Pakistan WEST CALDWELL, N.J. and TORONTO, ON / ACCESSWIRE / October 3, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological develo...
Source: ACCESSWIRE
Date: October, 03 2018 09:15
EastGate Biotech Signs Definitive Investment and European Licensing Agreement With Nico Innovagroup S.r.l. for Liquid Insulin Mouth Rinse Solution
Non-Dilutive Investment and Product License Includes Licensing Fee and Development Costs WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / August 27, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specificall...
Source: ACCESSWIRE
Date: August, 27 2018 09:00
EastGate Biotech Provides Update on Investment From Genluiching Mining Corporation
EastGate to Receive the First Non-dilutive Investment Tranch from the Total Funding up to $5 million USD as per the Terms of the Definitive Agreement WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / July 24, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that f...
Source: ACCESSWIRE
Date: July, 24 2018 09:30
EastGate Biotech Expands Indications of Liquid Insulin Mouth Rinse Solution to Alzheimer's Disease with Joint Venture Partner Genome Pharmaceuticals
Genome Pharma is the Parent Company of Netris/Origin BioPharmaceuticals the Company's Joint Venture Partner WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / June 28, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological develo...
Source: ACCESSWIRE
Date: June, 28 2018 08:00
EastGate Biotech Unveils Manufacturing Plans in an MOU with Mystic Pharmaceuticals Limited for Its Liquid Insulin Mouth Rinse Solution
WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / June 21, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the treatment of Type 2 diabetes, announced it entered into a Mem...
Source: ACCESSWIRE
Date: June, 21 2018 09:30
EastGate Biotech Strikes Investment and Licensing Collaboration with Nico Innovapharma for Liquid Insulin Mouth Rinse Solution for the European Market
Investment and Product License Includes Licensing Fee and Development Costs WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / June 19, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin dr...
Source: ACCESSWIRE
Date: June, 19 2018 09:15
EastGate Biotech Enters Into a Financial Agreement
Terms of the Agreement reflects long term vision and supports company's business plan WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / May 2, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in in...
Source: ACCESSWIRE
Date: May, 02 2018 09:00
EastGate Biotech Announces Joint Venture With Netris/Origin Biopharmaceuticals for Pakistani Market
Drug Development and Nutraceuticals Covered in JV WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / April 17, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery for the trea...
Source: ACCESSWIRE
Date: April, 17 2018 09:30
EastGate Biotech Announces Definitive Agreement with Genluiching Mining Corporation
EastGate to Receive Funding in Tranches Up to $5 million USD WEST CALDWELL, NJ and TORONTO, ON / ACCESSWIRE / April 10, 2018 / EastGate Biotech Corp. (OTC PINK: ETBI), a pharmaceutical company that focuses on innovative technological developments specifically in insulin drug delivery f...
Source: ACCESSWIRE
Date: April, 10 2018 09:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.00440.0050.0050.0042,545,200
2018-12-130.00510.00470.00510.0047132,000
2018-12-120.00510.00510.00510.0045381,825
2018-12-110.0050.00510.00510.00590,000
2018-12-100.0050.00490.00510.0047120,200

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-142,515,0002,545,20098.8135Short
2018-12-13132,000132,000100.0000Short
2018-12-12360,000381,82594.2840Short
2018-12-1180,00090,00088.8889Short
2018-12-1050,100120,20041.6805Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ETBI.


About Eastgate Biotech Corp. (OTC: ETBI)

Logo for Eastgate Biotech Corp. (OTC: ETBI)

EastGate Biotech produces and distributes innovative and healthy nutraceuticals that are based on natural therapies and absorbed naturally by the body. We utilize state of the art nanotechnologies to deliver healthy alternatives to conventional pharmaceuticals that all too often create dangerous side effects and unexpected consequences for those trying to attain and maintain healthy lives. Our research and development scientists have more than years of combined experience and are dedicated to providing the best nutraceutical products for your natural comfort, health, and well being.

 

Contact Information

 

 

Current Management

  • Anna Gluskin / CEO
  • Rose C. Perri / COO
  • Brian Lukian / CFO
  • Adrian McKenzie / Consultant
  • Anna Gluskin / Chairwoman

Current Share Structure

  • Market Cap: $2,406,867 - 03/13/2018
  • Authorized: 450,000,000 - 01/02/2018
  • Issue and Outstanding: 422,257,377 - 01/02/2018

 


Recent Filings from (OTC: ETBI)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 01 2018
Amendment to a previously filed 10-Q
Filing Type: 10-Q/AFiling Source: edgar
Filing Date: March, 01 2018
Amendment to a previously filed 10-Q
Filing Type: 10-Q/AFiling Source: edgar
Filing Date: March, 01 2018
Amendment to a previously filed 10-Q
Filing Type: 10-Q/AFiling Source: edgar
Filing Date: March, 01 2018

 

 


Daily Technical Chart for (OTC: ETBI)

Daily Technical Chart for (OTC: ETBI)


Stay tuned for daily updates and more on (OTC: ETBI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ETBI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ETBI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ETBI and does not buy, sell, or trade any shares of ETBI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/